RASolute 303Daraxonrasib Monotherapy or in Combination for Metastatic Pancreatic Adenocarcinoma

This study focuses on treating metastatic pancreatic adenocarcinoma, a type of cancer that has spread from the pancreas to other parts of the body. The main goal is to test if a drug called daraxonrasib, used alone or in combination with gemcitabine and nab-paclitaxel, can improve survival rates compared to the standard treatment of gemcitabine and nab-paclitaxel. This research is important as it aims to find better treatment options for this serious condition, potentially improving the care and life expectancy of affected patients. Participants in this study are randomly assigned to one of three groups. The first group receives daraxonrasib only, the second group receives daraxonrasib plus gemcitabine and nab-paclitaxel, and the third group receives the standard treatment of gemcitabine and nab-paclitaxel. The study measures the effectiveness of these treatments by looking at overall survival, which is the time from the start of the study until death from any cause, and progression-free survival, which is the time until the disease worsens or death occurs. The study uses established criteria to assess the progression of the disease.